Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2476 to 2490 of 9044 results

  1. Mavorixafor for treating WHIM syndrome [ID3946]

    Awaiting development Reference number: GID-TA10833 Expected publication date: TBC

  2. Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915]

    Awaiting development Reference number: GID-TA10791 Expected publication date: TBC

  3. Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]

    Awaiting development Reference number: GID-TA10776 Expected publication date: TBC

  4. Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]

    Awaiting development Reference number: GID-TA10662 Expected publication date: TBC

  5. Adrenal dysfunction

    Awaiting development Reference number: GID-QS10038 Expected publication date: TBC

  6. Iberdomide with dexamethasone and daratumumab for treating relapsed or refractory multiple myeloma after 1 or 2 lines of treatment [TSID12415]

    Awaiting development Reference number: GID-TA12466 Expected publication date: TBC

  7. Renal sympathetic denervation for resistant hypertension

    In development Reference number: GID-HTG10527 Expected publication date: TBC

  8. Upadacitinib for treating moderately to severely active systemic lupus erythematosus [TSID12366]

    Awaiting development Reference number: GID-TA12021 Expected publication date: TBC

  9. Semaglutide for managing overweight and obesity in children 6 to 11 years [TSID12381]

    Awaiting development Reference number: GID-TA12020 Expected publication date: TBC

  10. Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [ID6627]

    Awaiting development Reference number: GID-TA11526 Expected publication date: TBC

  11. Lymphatico-venous anastomosis for chronic lymphoedema

    Topic prioritisation

  12. Image-guided high intensity focused ultrasound to treat breast cancer

    Topic prioritisation

  13. Electrically-stimulated intravesical chemotherapy for non-muscle invasive bladder cancer

    Topic prioritisation

  14. Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]

    Awaiting development Reference number: GID-TA10723 Expected publication date: TBC

  15. Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]

    In development Reference number: GID-TA10623 Expected publication date: TBC